Opinion

Video

BCG-Unresponsive NMIBC and Treatments

Author(s):

Mark D. Tyson, MD, MPH,Gary D. Steinberg, MD

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • When do you consider a patient to have BCG-unresponsive disease?
      • What treatment options are available for BCG-unresponsiveness/intolerance in patients?
      Related Videos
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      1 expert in this video
      BPH: The Patient Journey
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      How recombinant BCG could ease strain of supply issues
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      Related Content
      Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
      April 2nd 2025

      The importance of federal funding in cancer research: A call to action

      Michael S. Cookson, MD, MMHC
      "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      January 14th 2025

      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

      Wayne Kuang, MD Steven Maislos, MD
      Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
      Subcutaneous nivolumab under review in EU for solid tumors
      March 31st 2025

      Subcutaneous nivolumab under review in EU for solid tumors

      Hannah Clarke
      The European Commission must issue a decision on the application on or by June 2, 2025.
      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
      November 27th 2024

      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

      Wayne Kuang, MD Bilal Chughtai, MD
      Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
      RAG-01 elicits complete responses in NMIBC
      March 26th 2025

      RAG-01 elicits complete responses in NMIBC

      Hannah Clarke
      "The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
      Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC
      March 26th 2025

      Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

      Andrea Necchi, MD Hannah Clarke
      "Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
      © 2025 MJH Life Sciences

      All rights reserved.